Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals (IRWD) is a leader in gastrointestinal therapeutics, pioneering treatments for chronic conditions like IBS-C and CIC. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative updates including earnings reports, research breakthroughs, and partnership announcements. Our curated collection ensures you never miss critical information about IRWD's FDA submissions, pipeline advancements, or market expansion strategies.
Discover comprehensive coverage of:
• Clinical trial results
• Drug development progress
• Strategic collaborations
• Regulatory updates
Bookmark this page for streamlined access to verified information directly impacting IRWD's position in the biopharmaceutical sector.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will present pivotal Phase III data on linaclotide for treating functional constipation in children aged 6-17 at the 2023 Digestive Disease Week® (DDW) from May 6-9 in Chicago, IL. This condition affects around 6 million children in the U.S. An oral presentation will detail a clinical trial assessing the efficacy and safety of linaclotide 72 mcg in this age group. Four poster sessions will present further efficacy and safety data. Notably, the FDA granted Priority Review for a supplemental New Drug Application (sNDA) for linaclotide in pediatric use, with a PDUFA date set for June 14, 2023. Currently, there are no FDA-approved therapies for pediatric functional constipation. Ironwood continues to expand its research in this area.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2023 investor update conference call on May 4, 2023, at 8:30 a.m. Eastern Time. Participants can join by calling (888) 330-2384 (U.S./Canada) or (240) 789-2701 (international) with conference ID 4671230. The call will also be accessible via webcast on the company's website, which is recommended to access at least 15 minutes prior to the start time. A replay of the call will be available starting at 11:30 a.m. Eastern Time on the same day, and can be accessed until May 18, 2023, by calling (800) 770-2030 (U.S./Canada) or (647) 362-9199 (international), also using conference ID 4671230. Ironwood Pharmaceuticals is focused on advancing treatments for gastrointestinal diseases.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its participation in two upcoming investor conferences:
- Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:10 a.m. ET in Boston.
- Barclays Global Healthcare Conference on March 14, 2023, at 8:00 a.m. ET in Miami.
Live webcasts of these events will be available on Ironwood's website, with replays accessible for 14 days post-conference. As a leading gastrointestinal healthcare company, Ironwood focuses on advancing treatments for GI diseases, notably through its product LINZESS® for managing IBS-C and CIC.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
